Результаты поиска

Связанные с сексом различия в болезни Хантингтона: обзор аналитического исследования.

Болезнь Хантингтона (HD) — это аутосомное и доминирующее нейродегенеративное расстройство, и новые данные свидетельствуют о различиях по признаку пола в проявлении и прогрессировании болезни. ЦЕЛЬ: Обобщение текущих данных о связанных с половой принадлежностью различиях в HD в генетических, клинических, биомаркетных и лечебных областях и выявление пробелов в знаниях. МЕТОДЫ: Поиск литературы был проведен в PubMed и Google Study (до 31.01.2026). В рамках соответствующих исследований были изучены гендерные или гендерные различия в отношении лиц с генетически подтвержденным врачом или лиц, подвер

Repetitive Transcranial Magnetic Stimulation: Is it an Effective Treatment for Cancer Pain?

Cancer is a major public health issue, with an estimated 20 million new cases and 9.7 million cancer-related deaths worldwide in 2022. Approximately 44.5% of patients experience cancer pain, significantly impacting their quality of life and causing physical and psychological burdens. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique, shows potential in managing cancer pain. This review summarizes current research on rTMS for cancer pain, focusing on pain directly caused by tumors, pain from cancer treatments, postoperative pain, and cancer-related sy

Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.

Renal impairment (RI) is a common complication of multiple myeloma (MM), which is associated with poor prognosis. Here, we revealed the association between regular examination data and RI incidence, RI response and survival in newly diagnosed multiple myeloma (NDMM) patients. A retrospective analysis was conducted on the initial clinical data of 647 NDMM patients, comprising 193 patients (29.83%, 193/647) with RI and 454 (70.17%, 454/647) without RI at diagnosis. Logistic regression analyses, both univariate and multivariate, were performed to identify the independent influencing factors of RI

Обновленная информация о соответствующей последовательности для спасательной терапии в Мультимиломе.

Нынешние стратегии лечения привели к непредсказуемым улучшениям в управлении миеломой (ММ) с течением времени. Вместе с тем в последние годы все более серьезной проблемой становится сопротивление лечению, особенно в том, что касается рефракции линалидомида и, в последнее время, рефрагментации даратумумаба и линалидомида, даже в условиях первой линии. Это сопротивление осложняет идентификацию алгоритма оптимального лечения для пациентов с рецидивом/отходом MM, особенно при первом рецидиве. В ходе этого обзора мы сосредоточим внимание на нынешних стратегиях в отношении пациентов, страдающих от С

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endpoints are determination of safety and the recommended IT nivolumab dose. The secondary endpoint is overall survival (OS). Patients are treated with IT nivolumab alone in cycle 1 and IV nivolumab is included in subsequent cycles. We treated 25 patients with metastatic melanoma using 5, 10, 20 and 50

From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells.

The insurgence of drug resistance in treating Multiple Myeloma (MM) still represents a major hamper in finding effective treatments, although over the past decades new classes of drugs, such as proteasome inhibitors and immunomodulatory drugs, have been discovered. Recently, our research team, within a Nature-Aided Drug Discovery project, isolated from Hibiscus Sabdariffa L. calyces the secondary metabolite called Hib-ester which possesses antiproliferative properties against human multiple myeloma RPMI 8226 cells, reduces migration and cell invasion and inhibits proteasome without neurotoxic

Classification of Health-Related Social Media Posts: Evaluation of Post Content-Classifier Models and Analysis of User Demographics.

BackgroundThe increasing volume of health-related social media activity, where users connect, collaborate, and engage, has increased the significance of analyzing how people use health-related social media.ObjectiveThe aim of this study was to classify the content (eg, posts that share experiences and seek support) of users who write health-related social media posts and study the effect of user demographics on post content.MethodsWe analyzed two different types of health-related social media: (1) health-related online forums-WebMD and DailyStrength-and (2) general online social networks-Twitt

Совпадение в полном тексте источника
… MOODY BLUES Career Changes Cerebral Palsy | Trying To Conceive Neuropathy Pregnancy Miscarriage Polycystic Ovarian Syndrome (PCOS) Cerebral Palsy Endometriosis Pseudotumor Cerebri Sexually Transmitted Diseases–Female Schizophrenia 35-44 | Vow To Live LGBT Against Suicide Parenting 'Tweens (9-12) Twins, Triplets …

Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.

Lung diseases, including COVID-19 and lung cancers, is a huge threat to human health. However, for the treatment and diagnosis of various lung diseases, such as pneumonia, asthma, cancer, and pulmonary tuberculosis, are becoming increasingly challenging. Currently, several types of treatments and/or diagnostic methods are used to treat lung diseases; however, the occurrence of adverse reactions to chemotherapy, drug-resistant bacteria, side effects that can be significantly toxic, and poor drug delivery necessitates the development of more promising treatments. Nanotechnology, as an emerging t

Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs.

AbstractThe treatment paradigm for lymphoma, a highly heterogeneous group of hematologic malignancies, has been revolutionized by the development of therapies targeting oncogenic signaling pathways. This shift from conventional chemotherapy to precision medicine is driven by a deep molecular understanding of the pathways that govern lymphoma cell survival and proliferation. This review comprehensively surveys the landscape of these targeted therapies, from fundamental molecular mechanisms to clinical breakthroughs. We first dissect the molecular architecture of key oncogenic drivers, covering

Совпадение в полном тексте источника
… significantly improved the ORR and PFS compared to obinutuzumab monotherapy, establishing a new chemotherapy-free option for this indolent malignancy [Table 1 ]. [ 33 ] Pushing the chemotherapy-free boundary into the frontline setting for aggressive lymphomas, the phase II POLARIS trial evaluated a novel triplet … 253 , 254 ] In the realm of cellular therapy, epigenetic priming with agents like decitabine before CAR-T cell infusion has been shown to improve patient outcomes in R/R DLBCL, likely by resensitizing chemoresistant cells. [ 249 , 250 ] Future strategies will undoubtedly focus on creating synergistic triplets …

Multiple Myeloma Therapy: Emerging Trends and Challenges.

Multiple myeloma (MM) is a complex hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow that secrete large amounts of immunoglobulins and other non-functional proteins. Despite decades of progress and several landmark therapeutic advancements, MM remains incurable in most cases. Standard of care frontline therapies have limited durable efficacy, with the majority of patients eventually relapsing, either early or later. Induced drug resistance via up-modulations of signaling cascades that circumvent the effect of drugs and the emergenc

Структурно-ориентированное понимание специфичности 2ДГ-III реберосчег.

Рибосчемы сохраняют некодированные домена РНК, в основном расположенные на 5'-конец бактериальных MRNA, которые служат регулятором генного экспрессии. Недавно третий класс 2Дексигуанозин реберосколка.2'-dG-III) был идентифицирован из семейства рибоколдов, проявляющих сопоставимую связь с 2ДиДжи, Гунанин и гуанозин. Чтобы прояснить уникальный механизм распознавания лиганда, мы раскрыли его кристаллы в комплексе с различными производными пурины, включая 2ДиДжи, Гунанин и гуанозин. Трехсторонняя структура показывает типичную архитектуру, похожую на вилку, с three вырезки, соединяющиеся в центре t

Наблюдение за финансовыми трудностями пациентов с множественной миеломой и хронической лимфоцитической лейкемией, проходящих лечение в онкологических клиниках США (Alliance A231602CD).

ЦЕЛИ: Оценка доли и корреляции финансовых трудностей, о которых сообщают сами пациенты с множественной миеломой (ММ) или хронической лимфоцитической лейкемией (КЛ). Вечеринка: Sixty-six Общинная практика США и практики меньшинств в области онкологии связана с Программой общинных онкологических исследований Национального института раковых заболеваний (НКОРП). Участники: в целом 521 (больные)≥18 С согласия MM или CLL и 416 :: ответы на опрос (процент завершения)79.8%). Респонденты имели диагноз MM (MM-диагностика)74.0%), степень бакалавра или выше (53.4%), белые (или белые).89.2%), застрахованны

Advanced Lung Cancer Inflammation Index: A Novel Comprehensive Biomarker of Host Status for Patients with Metastatic Colorectal Cancer.

Numerous biomarkers that reflect host status have been identified for patients with metastatic colorectal cancer (mCRC). However, there has been a paucity of biomarker studies that comprehensively indicate body composition, nutritional assessment, and systemic inflammation status. The advanced lung cancer inflammation index (ALI), initially introduced as a screening tool for patients with non-small-cell lung cancer in 2013, emerges as a holistic marker encompassing all body composition, nutritional status, and systemic inflammation status. The index is calculated by the simple formula: body ma

Beyond BCMA: newer immune targets in myeloma.

AbstractThe identification and targeting of B-cell maturation antigen (BCMA) through immunotherapeutic strategies such as antibody-drug conjugates, chimeric antigen receptor T cells, and T-cell engagers have revolutionized the care of patients with multiple myeloma (MM). These treatment modalities have improved the survival outcomes of patients with relapsed and/or refractory MM compared with previously established strategies and are moving into earlier lines of therapy. Despite their efficacy, the majority of patients eventually relapse, necessitating additional therapeutic targets for salvag

Моноклональная антитела в Смолдингах Множественная Миелома и Моноклональная Гаммопатия Неопределенной Значимости: Текущий статус и будущие направления.

Моноклональные антитела (MoAbs), предназначенные для нескольких клеточных рецепторов, значительно улучшили прогноз множественных миелом (MM). Их высокая эффективность и безопасность поднимают вопрос о том, влияет ли на естественный ход болезни более раннее терапевтическое вмешательство в моноколональную гаммопатию неопределенного значения (МГУС) и задушающую миелому (ШМ). ММ предшествует клинически признанным условиям, таким, как МГУС и SMM. В рамках многочисленных исследований изучается биология заболеваний и иммунный профиль SMM и MGUS, с тем чтобы разгадать сложную связь между иммуноконтрол

Совпадение в полном тексте источника
… Furthermore, the transition from triplets to quadruplets incorporating MoAbs has not resulted in a decrease in patients’ quality of life, attributable to their mechanism of action and safety profile [ 2 , 3 ]. Smoldering Multiple Myeloma is an asymptomatic stage between MGUS and active MM [ 5 ]. …

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

Despite the improvement in survival outcomes, multiple myeloma (MM) remains an incurable disease. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) represents a new strategy for the treatment of relapsed/refractory MM (R/R). In this paper, we describe several recent advances in the field of anti-BCMA CAR T-cell therapy and MM. Currently, available data on anti-BCMA CART-cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated R/R MM patients. Despite this, the main issues remain to be addressed. First of all, a significant pro

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma.

BackgroundNovel therapies for multiple myeloma (MM) promise to improve outcomes but are also associated with substantial increasing costs. Evidence regarding cost-effectiveness of novel treatments is necessary, but a comprehensive up-to-date overview of the cost-effectiveness evidence of novel treatments is currently lacking.MethodsWe searched Embase, Medline via Ovid, Web of Science and EconLIT ProQuest to identify all cost-effectiveness evaluations of novel pharmacological treatment of MM reporting cost per quality-adjusted life year (QALY) and cost per life year (LY) gained since 2005. Qual

Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.

Vitamin D is a steroid hormone that is essential for bone mineral metabolism and it has several other effects in the body, including anti-cancer actions. Vitamin D causes a reduction in cell growth by interrupting the cell cycle. Moreover, the active form of vitamin D, i.e., 1,25-dihydroxyvitamin D, exerts various effects via its interaction with the vitamin D receptor on the innate and adaptive immune system, which could be relevant in the onset of tumors. Multiple myeloma is a treatable but incurable malignancy characterized by the growth of clonal plasma cells in protective niches in the bo

Совпадение в полном тексте источника
… Survival rates have improved over the last 10 years using novel agents such as triplets of several generations of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs), mono- and bi-clonal antibodies (moAbs and BiTEs), new alkylating agents (Melflufen), chimeric antigen receptor (CAR) T-cell …

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

BackgroundPatients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent between individual studies. Minimal data are available on the effect of maintenance lenalidomide in more aggressive disease states, such as patients with cytogenetic high-risk disease or patients ineligible for transplantation. We aimed to assess lenalidomide maintenance versus observation in patien

Совпадение в полном тексте источника
… Patients receiving immunomodulatory-based triplets (CTD vs CRD) followed a response-adapted approach: those with complete response or very good partial response (assessed according to International Myeloma Working Group [IMWG] criteria) proceeded to autologous stem-cell transplantation in the transplantation-eligible …

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.

Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined high-risk disease. However, resistance to bortezomib and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib demonstrates promising activity in myeloma patients who are